Day: November 24, 2025

Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) — Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the acceptance of an abstract for a Late Breaking Clinical Trial Update presentation at the upcoming Paris Vascular Insights (PVI) 2025, being held on December 11-13, 2025, in Paris, France. Presentation:Title Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)   Presenter Peter Schneider, M.D., Professor of Surgery,...

SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Director of Quality Assurance and Regulatory Compliance at Moximed, (an orthopedic device company), and as Senior Director, Quality Engineering at...

CORNELIUS, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) — Alpha Modus, Corp., a U.S.-based retail technology company and subsidiary of Alpha Modus Holdings, Inc. (NASDAQ: AMOD), today announced the filing of two coordinated patent infringement lawsuits against V-Count Global Holding Ltd. in the Eastern District of Texas and Stratacache, Inc. in the Central District of California. The complaints assert core patents that form the backbone of Alpha Modus’ real-time retail intelligence stack covering shopper-behavior analytics, product-interaction tracking, sentiment detection, store-layout optimization, inventory intelligence, digital engagement, and point-of-sale workflow automation. These patents, some originating from inventions dating back to 2013, are the foundation of technologies Alpha Modus has spent years deploying, commercializing,...

Nanox’s HealthOST and HeathVCF recommended for use in UK National Health Service hospitals for a three-year period as the use of AI solutions in bone disease is evaluated PETACH TIKVA, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI Ltd (“Nanox. AI”, secured the recommendation of the National Institute for Health and Care Excellence (NICE), the UK’s clinical standards and reimbursement body. NICE has included both Nanox AI bone solutions in an Early Value Assessment at National Health Service (NHS) hospitals in the UK. NICE has included Nanox AI’s HealthVCF and HealthOST, along with three other AI solutions, for evaluation in NHS hospitals to provide...

TORONTO, Nov. 24, 2025 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (TSX: CNE) (OTCQX: CNNEF) (BVC: CNE.C) (“Canacol” or the “Company”), announces that the Company and certain of its subsidiaries filed for relief under Chapter 15 of the U.S. Bankruptcy Code in the Bankruptcy Court for the Southern District of New York. The petitions for relief seek recognition of the Company’s Canadian proceeding commenced under the Companies’ Creditors Arrangement Act, or CCAA, in the Court of King’s Bench of Alberta as a foreign main proceeding. Relief under Chapter 15 of the U.S. Bankruptcy Code is intended to safeguard a company’s U.S.-based assets and facilitate cooperation between U.S. courts and foreign judicial proceedings. In conjunction with the petitions, the foreign representative sought provisional relief and a stay of proceedings...

Strategic Acquisition Grows World’s Largest Privately Owned Super Scooper Fleet by 33% from 6 to 8 Aircraft BELGRADE, Mont., Nov. 24, 2025 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it has entered into a purchase agreement for two Canadair CL-215T Amphibious Aircraft from MAB Funding, LLC, the partnership between Bridger, Marathon Asset Management LP and Eyre Street Capital. The purchase increases Bridger’s Super Scooper fleet from six to eight aircraft and solidifies its position as the owner of the largest private Super Scooper fleet in the world. “The addition of these two Super Scoopers is an incredible step for the Company,” said Sam Davis, Chief Executive Officer of Bridger...

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst’s management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Monday, December 8, 2025. Date of Presentation: Monday, December 8, 2025Time: 12:35pm ETWebcast Link The webcast will be available under the Investors section on the Company’s website, www.catalystpharma.com, and a replay will be available for at least 30 days. About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals,...

OREM, Utah, Nov. 24, 2025 (GLOBE NEWSWIRE) — SunPower Inc. (“SunPower” or the “Company”) (Nasdaq: SPWR) a solar technology, services, and installation company, today announced that on November 21, 2025 it made inducement grants to two key employees of Ambia Energy as a material inducement to employment with SunPower following its acquisition of Ambia Energy. The inducement grants consist of time-based restricted stock units (“RSUs”) for a total of 2.0 million shares of SunPower common stock, with 20% of the RSUs vesting one year after grant and the remainder vesting in equal monthly installments thereafter until the fifth anniversary of the grant date, with such vesting subject to the RSU recipient’s continuous service through each vesting date. The RSUs are also subject to accelerated vesting in the event the RSU recipient’s employment...

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) is pleased to announce the appointment of Mr. Jasper Bertisen to its Board of Directors effective immediately. Jasper is a seasoned mining executive with over two decades of leadership experience in global mining investment and governance, with a strong background in the evaluation of mining projects from both technical and financial perspectives. He has spent most of his career in mining private equity with Resource Capital Funds, overseeing due diligence and strategy execution for investments spanning exploration to production stage assets across various commodities and jurisdictions. As a former Partner at Resource Capital Funds, he oversaw an $800 million portfolio and contributed...

– Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation – built for transparency, automation, and community participation. – Mr. Matteo Renzi, former Prime Minister of Italy, will be appointed to the Enlivex Board of Directors following closing of the private placement. – Enlivex to continue clinical development of Allocetra™, a potentially game-changing knee osteoarthritis therapeutic, a growing market with significant unmet medical need. – Price per share of $1.00, representing a premium of 11.5% from previous...